TNFRSF17 and neoplasm: Bispecific BC19 CAR‐T cells,[19] which can target tumor cells overexpressing BCMA (B Cell Maturation Antigen) and CD19 (Cluster of Differentiation 19) antigens both in vitro and in vivo, were fabricated and utilized as the target cells for this research.